製品番号: HY-N0787

Cryptochlorogenic acid

(別名: 4-Caffeoylquinic acid; 4-O-Caffeoylquinic acid; 4-O-カフェオイルキナ酸; クリプトクロロゲン酸)

6 Cited Publications

カスタマーレビュー

Based on 6 publication(s) in Google Scholar

Cryptochlorogenic acid (4-Caffeoylquinic acid) is a naturally occurring phenolic acid compound with oral effectiveness, anti-inflammatory, antioxidant and anti-cardiac hypertrophy effects. Alleviating LPS (HY-D1056) and ISO (HY-B0468) by regulating proinflammatory factor expression, inhibiting NF-κB activity, promoting Nrf2 nuclear transfer, and regulating PI3Kα/Akt/ mTOR / HIF-1α signaling pathway Induced physiological stress response.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.23%
CAS 番号: 905-99-7
分子式: C₁₆H₁₈O₉
分子量:354.31

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Cryptochlorogenic acid 構造式

CAS 番号: 905-99-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (6)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

HIF-1α

Endogenous Metabolite アイソフォーム固有の製品をすべて表示 :

NF-κB アイソフォーム固有の製品をすべて表示 :

mTOR アイソフォーム固有の製品をすべて表示 :

HIF/HIF Prolyl-Hydroxylase アイソフォーム固有の製品をすべて表示 :

体外実験

Cryptochlorogenic acid (0-150 μM, 12, 24 or 48 h) shows low toxicity to RAW264.7 cells and does not significantly affect the viability of RAW264.7 cells at specific concentrations^[2].
Cryptochlorogenic acid (20-80 μM, 2 h) can dose-dependent inhibit lipopolysaccharide (LPS: 1 μg/mL, 24 h) in RAW264.7 cells. induced the production of nitric oxide (NO), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), blocking the expression of iNOS, COX-2, TNF-α and IL-6^[2].
Cryptochlorogenic acid (20-80 μM, 2 hours) inhibits the phosphorylation of IκB kinase (IKK), degrades I-κB, and reduces the nuclear translocation of NF-κB. At the same time, CCGA downregulates the phosphorylation level of MAPKs. Overall, CCGA effectively controls the expression of pro-inflammatory factors, thereby alleviating LPS-induced (1 μg/mL, 24 h) inflammation. It also promotes the nuclear translocation of Nrf2 to inhibit oxidative stress^[2].
Cryptochlorogenic acid (1-200 μM, 48 hours) can effectively reduce the myocardial hypertrophy of H9c2 cells caused by ISO at a certain concentration. Cryptochlorogenic acid regulates the PI3Kα/Akt/mTOR/HIF-1α signaling pathway by significantly inhibiting the phosphorylation expression level of mTOR and over-expression of p-Akt and HIF-1α induced by ISO^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

RAW264.7 cells
Concentration:

Cryptochlorogenic acid: 20-80 μM, LPS: 1 μg/mL
Incubation Time:

Cryptochlorogenic acid: 2 h, LPS: 24 h
Result:

Significantly inhibited the protein levels of iNOS, COX-2, IL-6, TNF-α and TLR4 in RAW264.7 macrophages stimulated by LPS.
Significantly inhibited the phosphorylation and degradation of IκB and the phosphorylation of IKKα/β induced by LPS.
Dose-dependent reduction of LPS-induced NF-κB(p65) transfer from cytoplasm to nucleus.
Significantly inhibited the phosphorylation of JNK1/2, ERK1/2, and p38 proteins induced by LPS.
significantly up-regulated Nrf2 protein levels in the nucleus and decreased NRF2 protein levels in the cytoplasm in a dose-dependent manner.

Cell Viability Assay^[2]

Cell Line:

RAW264.7 cells
Concentration:

Cryptochlorogenic acid (CCGA) : 0-150 μM, LPS (HY-D1056) : 0-3 μg/ml
Incubation Time:

12, 24 or 48 h
Result:

At doses of 150 μM and 100 μM, slight toxicity was shown to RAW264.7 cells with no significant decrease in cell viability.
RAW264.7 cells showed no toxicity after being treated with LPS at different concentrations for 12 hours. After being treated with LPS above 2 μg/ml for 24h, the cell viability decreased significantly.
Treated with 0-100 μM CCGA and 1 μg/ml LPS for 24 h, RAW264.7 cells had low toxicity and no significant effect on cell viability.

RT-PCR^[3]

Cell Line:

H9c2 Cells
Concentration:

1-200 μM
Incubation Time:

48 h
Result:

Significantly decreased the expression levels of ANP, BNP and HIF-1α mRNA in H9c2 cells after ISO treatment.

体内実験

Pharmacokinetic parameters of Cryptochlorogenic acid after intragastric administration of Cryptochlorogenic acid at three dosages^[2]

Dose (mg/kg)	C_max (μg/L)	t_max (h)	t_1/2 (h)	AUC_0-t (μg•h/L)	AUC_0-∞ (μg•h/L)	MRT_0-t (h)	MRT_0-∞ (h)
100	630	0.33	2.00	1938.91	1977.70	3.21	3.51
200	1270.09	0.47	1.97	3071.87	3179.41	3.23	3.39
400	2582.68	0.44	2.34	8825.32	9139.54	3.47	3.93

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 905-99-7
性状 Solid
分子量 354.31
分子式 C₁₆H₁₈O₉
Color White to off-white
SMILES

O=C(/C=C/C1=CC(O)=C(O)C=C1)O[C@@H]([C@@H]2O)[C@@H](C[C@](C(O)=O)(O)C2)O
別名

4-Caffeoylquinic acid; 4-O-Caffeoylquinic acid; 4-O-カフェオイルキナ酸; クリプトクロロゲン酸
Structure Classification
- Phenylpropanoids
- Simple Phenylpropanols
- Phenols
- Polyphenols
Initial Source
- Endogenous metabolite
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (6)

All

Sort by:

Journal Impact Factor

Phytomedicine

A novel mechanism of Reduning injection in sepsis treatment: Targeting inflammatory kinases TBK1 and IKKβ. [Abstract]

2026 Feb:151:157776. PMID: 41512388
Lwt-Food Sci Technol

December 2021, 112343.
Aquaculture

2026 Feb 12.
Discov Oncol

UCHL1 promotes osteosarcoma progression via deubiquitination and stabilization of LDHB. [Abstract]

2026 Apr 17;17(1):808. PMID: 41998400
SSRN

2026 Apr 8.
Chemistry of Plant Raw Material

2025.

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (141.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8224 mL

14.1119 mL

28.2239 mL

5 mM

0.5645 mL

2.8224 mL

5.6448 mL

10 mM

0.2822 mL

1.4112 mL

2.8224 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (7.06 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Wang Jing, ea al.Simultaneous determination of chlorogenic acid,cryptochlorogenic acid,caffeic acid,naringin,hesperidin and linarin in Xiao′erjinning oral liquid by an HPLC method. China Journal of Chinese Materia Medica, 2010-13

[2]. Zhao XL, et al. Cryptochlorogenic acid attenuates LPS-induced inflammatory response and oxidative stress via upregulation of the Nrf2/HO-1 signaling pathway in RAW 264.7 macrophages. Int Immunopharmacol. 2020;83:106436. [Content Brief]

[3]. Li J, et al. Cryptochlorogenic acid and its metabolites ameliorate myocardial hypertrophy through a HIF1α-related pathway. Food Funct. 2022;13(4):2269-2282. Published 2022 Feb 21. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8224 mL	14.1119 mL	28.2239 mL	70.5597 mL
	5 mM	0.5645 mL	2.8224 mL	5.6448 mL	14.1119 mL
	10 mM	0.2822 mL	1.4112 mL	2.8224 mL	7.0560 mL
	15 mM	0.1882 mL	0.9408 mL	1.8816 mL	4.7040 mL
	20 mM	0.1411 mL	0.7056 mL	1.4112 mL	3.5280 mL
	25 mM	0.1129 mL	0.5645 mL	1.1290 mL	2.8224 mL
	30 mM	0.0941 mL	0.4704 mL	0.9408 mL	2.3520 mL
	40 mM	0.0706 mL	0.3528 mL	0.7056 mL	1.7640 mL
	50 mM	0.0564 mL	0.2822 mL	0.5645 mL	1.4112 mL
	60 mM	0.0470 mL	0.2352 mL	0.4704 mL	1.1760 mL
	80 mM	0.0353 mL	0.1764 mL	0.3528 mL	0.8820 mL
	100 mM	0.0282 mL	0.1411 mL	0.2822 mL	0.7056 mL

Keywords

Cryptochlorogenic acid

6 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Cryptochlorogenic acid

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Cryptochlorogenic acid

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

NF-κB アイソフォーム固有の製品をすべて表示

mTOR アイソフォーム固有の製品をすべて表示

HIF/HIF Prolyl-Hydroxylase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (6)